A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab-refractory iNHL (COMPLEMENT A + B study)

Files in this item
Date
2021Author
Rummel, Mathias J.
Janssens, Ann
MacDonald, David
Keating, Mary-Margaret
Zaucha, Jan M.
Davis, Jaclyn
Lasher, Janet
Babanrao Pisal, Chaitali
Izquierdo, Miguel
Friedberg, Jonathan W.
Quotable link
http://dx.doi.org/10.22029/jlupub-9112Original publication in
British journal of haematology 193 (2021), 1123-1133